SCHEMBL16465352

SCHEMBL16465352

NC(=O)c1cnc(Nc2ccc(C3CCN(S(=O)(=O)C4CC4)CC3)cc2)nc1NC1CC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 0.83
JAK1 P23458 3/20 0.66
JAK2 O60674 2/20 0.66
JAK3 P52333 2/20 0.66
CHEK1 O14757 2/20 0.65
RET P07949 2/20 0.65
TYK2 P29597 2/20 0.65
FLT3 P36888 2/20 0.65
RPS6KA3 P51812 2/20 0.65
MAPK10 P53779 2/20 0.65
STK4 Q13043 2/20 0.65
STK3 Q13188 2/20 0.65
MARK2 Q7KZI7 2/20 0.65
TBK1 Q9UHD2 2/20 0.65
RPS6KA6 Q9UK32 2/20 0.65
NUAK1 O60285 1/20 0.65
CSF1R P07333 1/20 0.65
FLT4 P35916 1/20 0.65
MAP3K9 P80192 1/20 0.65
ITK Q08881 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736263 0.91 SYK (1.00) SYKJAK1JAK2JAK3CHEK1
SCHEMBL16465834 0.90 SYK (0.85) SYKJAK1JAK2JAK3CHEK1
SCHEMBL16466446 0.89 SYK (0.83) SYKJAK1JAK2JAK3CHEK1
SCHEMBL16464522 0.88 SYK (0.82) SYKJAK1JAK2JAK3CHEK1
SCHEMBL736830 0.88 SYK (1.00) SYKJAK1JAK2JAK3CHEK1
SCHEMBL17076560 0.87 SYK (0.79) SYK
SCHEMBL17083656 0.87 SYK (0.77) SYKJAK1JAK2JAK3CHEK1
SCHEMBL17076546 0.87 SYK (0.82) SYK
SCHEMBL16465896 0.86 SYK (0.84) SYK
SCHEMBL17076530 0.85 SYK (0.74) SYKJAK1JAK2JAK3CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676756-B2 Substituted pyrimidinyl kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-06-13 US claimed
US-20150259328-A1 SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS ALEXION PHARMACEUTICALS, INC. 2015-09-17 US claimed
US-9676756-B2 Substituted pyrimidinyl kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-06-13 US disclosed
US-9676756-B2 Substituted pyrimidinyl kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-06-13 US disclosed
US-9676756-B2 Substituted pyrimidinyl kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-06-13 US disclosed
US-20150259328-A1 SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS ALEXION PHARMACEUTICALS, INC. 2015-09-17 US disclosed
US-20150259328-A1 SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS ALEXION PHARMACEUTICALS, INC. 2015-09-17 US disclosed
US-20150259328-A1 SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS ALEXION PHARMACEUTICALS, INC. 2015-09-17 US disclosed
EP-2903970-A2 SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS Portola Pharmaceuticals, Inc. (US) 2015-08-12 EP disclosed
WO-2014058921-A2 SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259328-A1 SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS SYK, JAK2, JAK1 SYK 1/4885JAK1 3/4885JAK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.